Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.64 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.64 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476070 | 1.00 | KDR (0.68) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL26546756 | 0.91 | KDR (0.76) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL14422910 | 0.87 | KDR (0.69) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL2600217 | 0.87 | KDR (0.69) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL14422909 | 0.86 | KDR (0.64) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL26545958 | 0.86 | KDR (0.64) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL28520609 | 0.85 | KDR (0.68) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL4443052 | 0.85 | KDR (0.71) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL13004812 | 0.85 | KDR (0.71) | KDRGAAALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL462753 | 0.84 | KDR (0.76) | KDRGAAALDH1A1KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017180063-A1 | A POTENTIAL COMBINATION THERAPY USING AN INHIBITOR OF GLUCOSE TRANSPORT AND AN INTRACELLULAR CALCIUM INDUCER TO TARGET CANCER METABOLISM | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2017-10-19 | — | — | WO | claimed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023114723-A2 | BIOMARKERS FOR DENDRITIC CELLS | PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20210214390-A1 | RAPAGLUTINS, NOVEL INHIBITORS OF GLUT AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-07-15 | — | — | US | disclosed |
| US-20210076956-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | Palo Alto Investors LP | 2021-03-18 | — | — | US | disclosed |
| US-10874685-B2 | Pancreatic cancer therapy and diagnosis | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-12-29 | — | — | US | disclosed |
| US-10835134-B2 | Methods and compositions for restoring homeostatic capacity of a subject | PALO ALTO INVESTORS (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200030356-A1 | PANCREATIC CANCER THERAPY AND DIAGNOSIS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-01-30 | — | — | US | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| WO-2008036244-A1 | USE OF CYCLOSPORIN A TO SENSITIZE RESISTANT CANCER CELLS TO DEATH RECEPTOR LIGANDS | THE BURHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | SLC2A1, SLC2A4, SLC2A2 | KDR 1124/4885GAA 183/4885ALDH1A1 2516/4885 |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | TNFRSF1A, TNFRSF9, CD40 | KDR 332/4885GAA 3830/4885ALDH1A1 3879/4885 |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | BAD, BAK1, MCL1 | KDR 594/4885GAA 4225/4885ALDH1A1 1027/4885 |
| US-20200030356-A1 | PANCREATIC CANCER THERAPY AND DIAGNOSIS | PNLIP, GPR119, PDK1 | KDR 927/4885GAA 205/4885ALDH1A1 1202/4885 |
| US-20210214390-A1 | RAPAGLUTINS, NOVEL INHIBITORS OF GLUT AND USE THEREOF | SLC2A1, SLC2A4, SLC2A2 | KDR 1124/4885GAA 183/4885ALDH1A1 2516/4885 |
| US-10874685-B2 | Pancreatic cancer therapy and diagnosis | PNLIP, RNASE1, GPR119 | KDR 1104/4885GAA 537/4885ALDH1A1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.